מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
PANITUMUMAB
AMGEN CANADA INC
L01FE02
PANITUMUMAB
200MG
SOLUTION
PANITUMUMAB 200MG
INTRAVENOUS
100
Schedule D
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0152457001; AHFS:
APPROVED
2008-04-03
_ _ _VECTIBIX Product Monograph _ _Page 1 of 62_ PRODUCT MONOGRAPH PR VECTIBIX (panitumumab) Sterile Solution for Infusion 100, 400 mg (20 mg/mL) Professed Standard Antineoplastic Amgen Canada Inc. 6775 Financial Drive, Suite 100 Mississauga, Ontario L5N 0A4 Date of Preparation: March 31, 2017 Submission Control No: 193962 © 2008-2017 Amgen Canada Inc., all rights reserved _ _ _VECTIBIX Product Monograph _ _Page 2 of 62_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 DESCRIPTION................................................................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 35 DOSAGE AND ADMINISTRATION ............................................................................. 35 OVERDOSAGE ............................................................................................................... 37 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 37 STORAGE AND STABILITY ......................................................................................... 39 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 39 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 39 PART II: SCIENTIFIC INFORMATION .......................... קרא את המסמך השלם